Sinobioway Enters $50 Million Deal for Five BioAtla CAB Candidates

Beijing Sinobioway added five new Conditionally Active Biologic antibody targets to its collaboration with BioAtla, a San Diego-Beijing biotech. Sinobioway will pay $50 million to BioAtla for China rights to the new targets, consisting of $30 million in cash and $20 million in manufacturing and development costs (at a discounted rate). In 2015, Sinobioway in-licensed greater China rights to four CAB candidates from BioAtla. The two companies have also signed a new services agreement that calls for Sinobioway to provide BioAtla with development and manufacturing services. More details.... Share this with colleagues: // //